The Agenda

The FDA and the Biosciences Non-Boom

Mike Masnick points us to an insightful Carl Schramm column published last month:

In the past 15 years, despite a doubling of federal funds for biomedical R&D, the number of new drugs approved by the FDA and coming to market has decreased by nearly half — from around 40 per year in the late 1990s to a little over 20 per year since 2005. Pre-market testing to meet FDA requirements has become such a huge factor in drug development budgets that it’s hard for companies to even consider working on new products with limited market potential.

Among other things, Schramm points to the onerous cost of drug trials and the increasing risks of tort liability as obstacles to new entrants. To break through the bottlenecks, Schramm recommends that the FDA focus on safety rather than efficacy, a question best left to decentralized markets:

The agency’s regimes for product testing and control need to be streamlined — perhaps by adopting a new, quicker-to-market model such as “adaptive” regulation — and some aspects could be stripped away entirely. One approach would be to have the FDA go on approving drugs and devices for safety, but let the market determine efficacy, at least to a greater extent than at present. Also, once a treatment has passed the FDA’s safety exam, why not reduce the added hurdle of tort liability by exempting the makers from punitive damages?

Masnick goes further still:

Obviously, those making medical products have every incentive to have those products actually work. Rather than saddling them with massive clinical testing regimes, why not focus on transparency, that would provide more data and opportunities for everyone to properly evaluate the effectiveness and risks of certain products? As it stands now, the data from most clinical trials is totally hidden away. Imagine a much more open process that would allow people to access the data, share their own data and determine what really is and is not safe. 

I like Masnick’s approach, but relying on transparency raises the question of how we’d handle tort liability for new drugs. My sense is that a bias towards transparency combined with Schramm’s call for limiting FDA efforts to determining the safety and not the efficacy of new drugs is a sound option, which might, if we’re lucky, accelerate the pace the medical innovation. 

If we get much better at finding low-cost drug therapies that can substitute for labor-intensive medical procedures, we’d also go a long way towards containing medical cost growth. 

Reihan Salam — Reihan Salam is executive editor of National Review and a National Review Institute policy fellow.

Most Popular


Holy Week with Saint Paul

Just the other day, I ordered a replacement copy of The Passion of the Christ -- it can be so impactful for Holy Week meditation. In the years since its release, it’s become something of required Lenten viewing for me. But this year, there is a new movie to help with prayer, Paul, Apostle of Christ, released ... Read More

Friday Links

UPS Trucks (Mostly) Don't Turn Left, Saving Them 10 Million Gallons of Gas Per Year. Scientists provide comprehensive breakdown of how much people poo in their lifetime. Famed archaeologist forged murals, inscriptions for decades. How Do You Make Beer in Space? Astronauts return to earth ... Read More

Heckuva Job, Paul and Mitch

As Thursday's editorial makes clear, the omnibus spending bill is a disgrace. That may be why about 40 percent of Republicans (and 40 percent of Democrats) voted against it. Apart from the absence of a DACA/Dream amnesty, the immigration portions represent a comprehensive victory by the anti-enforcement crowd. ... Read More
Politics & Policy

California’s Pro-Nuclear Renegade

If California’s upcoming gubernatorial race gets decided solely by money, Michael Shellenberger doesn’t have a chance. The latest campaign filings show that Shellenberger, an environmentalist from Berkeley, has about $37,000 in cash on hand. The frontrunner in the June 5 California primary, Lieutenant ... Read More